Advertisement
Australia markets closed

  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     

  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     

  • AUD/USD

    0.6618
    -0.0020 (-0.30%)
     

  • OIL

    78.49
    -0.13 (-0.17%)
     

  • GOLD

    2,348.40
    +30.40 (+1.31%)
     

  • Bitcoin AUD

    100,085.38
    -167.38 (-0.17%)
     

  • CMC Crypto 200

    1,372.13
    -45.75 (-3.23%)
     

  • AUD/EUR

    0.6178
    +0.0005 (+0.09%)
     

  • AUD/NZD

    1.0765
    +0.0012 (+0.12%)
     

  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     

  • NASDAQ

    19,659.80
    +82.88 (+0.42%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     

  • DAX

    18,002.02
    -263.66 (-1.44%)
     

  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

Veracyte to Participate in Upcoming Investor Conferences

Business Wire
·1-min read

SOUTH SAN FRANCISCO, Calif., May 15, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences.

  • Leerink Partners 2024 Healthcare Crossroads Conference – Austin, TX
    Fireside Chat on May 29th at 12:20 p.m. Eastern Time

  • William Blair 44th Annual Growth Stock Conference – Chicago, IL
    Presentation on June 4th at 5:40 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available following the conclusion of the live presentation broadcast.

ADVERTISEMENT

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515789405/en/

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413